Cargando…
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
BACKGROUND: Glucose-dependent insulinotropic peptide (GIP) is one of two incretin hormones that communicate nutrient intake with systemic metabolism. Although GIP was the first incretin hormone to be discovered, the understanding of GIP's biology was quickly outpaced by research focusing on the...
Autor principal: | Campbell, Jonathan E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085569/ https://www.ncbi.nlm.nih.gov/pubmed/33290902 http://dx.doi.org/10.1016/j.molmet.2020.101139 |
Ejemplares similares
-
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
por: Killion, Elizabeth A., et al.
Publicado: (2020) -
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
por: Mroz, Piotr A., et al.
Publicado: (2018) -
GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior
por: Samms, Ricardo J., et al.
Publicado: (2022) -
The future of EPAC-targeted therapies: agonism versus antagonism
por: Parnell, Euan, et al.
Publicado: (2015) -
Agonism and Antagonism at the Insulin Receptor
por: Knudsen, Louise, et al.
Publicado: (2012)